Oncternal Therapeutics Management
Management criteria checks 3/4
Oncternal Therapeutics' CEO is Jim Breitmeyer, appointed in Jun 2019, has a tenure of 4.83 years. total yearly compensation is $2.41M, comprised of 24.1% salary and 75.9% bonuses, including company stock and options. directly owns 1.22% of the company’s shares, worth $287.38K. The average tenure of the management team and the board of directors is 3 years and 4.8 years respectively.
Key information
Jim Breitmeyer
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 24.1% |
| CEO tenure | 4.8yrs |
| CEO ownership | 1.2% |
| Management average tenure | 3yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03
Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?
Mar 01Oncternal: Solid Data In Tough-To-Treat Cancer
Jan 31Oncternal Therapeutics: Recent Success Points To A Bright Future
Jan 29Oncternal inks manufacturing deal with Miltenyi Biotec subsidiary
Jan 14Oncternal and karolinska Institutet ink research deal for ROR1-targeting cell therapies
Jan 07Oncternal Therapeutics soars after presenting data at ASH
Dec 07Oncternal Therapeutics shares dip 20% after raising 'bought deal' offering to $22.5M
Nov 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$39m |
| Sep 30 2023 | n/a | n/a | -US$42m |
| Jun 30 2023 | n/a | n/a | -US$43m |
| Mar 31 2023 | n/a | n/a | -US$46m |
| Dec 31 2022 | US$2m | US$580k | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$39m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$5m | US$557k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | n/a | n/a | -US$21m |
| Mar 31 2021 | n/a | n/a | -US$18m |
| Dec 31 2020 | US$780k | US$530k | -US$17m |
| Sep 30 2020 | n/a | n/a | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$1m | US$502k | -US$34m |
| Sep 30 2019 | n/a | n/a | -US$31m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$518k | US$426k | -US$7m |
Compensation vs Market: Jim's total compensation ($USD2.41M) is above average for companies of similar size in the US market ($USD667.11K).
Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.
CEO
Jim Breitmeyer (69 yo)
4.8yrs
Tenure
US$2,407,906
Compensation
Dr. James B. Breitmeyer, also known as Jim, M.D., Ph D., served as Director of Otonomy, Inc. since June 20, 2018 until February 2023. He serves as Director of Rebalance Health, Inc. He serves as the Chief...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | US$2.41m | 1.22% $ 287.4k | |
| Chief Medical Officer | 2.9yrs | US$962.47k | 0.24% $ 56.4k | |
| CFO & Treasurer | 4.8yrs | US$1.98m | 0.27% $ 64.5k | |
| Chief Technical & Scientific Officer | 3.3yrs | no data | 0.082% $ 19.3k | |
| General Counsel & Secretary | 3yrs | no data | 0.16% $ 37.1k | |
| Senior Vice President of Corporate Development | 2.8yrs | no data | no data | |
| Senior Vice President of Human Resources | less than a year | no data | no data |
3.0yrs
Average Tenure
54yo
Average Age
Experienced Management: ONCT's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | US$2.41m | 1.22% $ 287.4k | |
| Independent Director | 17.9yrs | US$90.21k | 0.14% $ 32.4k | |
| Independent Director | 4.8yrs | US$80.71k | 0.022% $ 5.3k | |
| Independent Director | 4.8yrs | US$80.21k | 0.053% $ 12.4k | |
| Independent Chairman of the Board | 4.8yrs | US$126.81k | 0.027% $ 6.3k | |
| Independent Director | 3.3yrs | US$72.21k | 0.0051% $ 1.2k | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 4.8yrs | US$72.21k | 0.031% $ 7.3k | |
| Non-Independent Director | 4.8yrs | US$68.21k | 0.37% $ 87.6k | |
| Cell Therapy Scientific Advisory Board Member | 2.4yrs | no data | no data | |
| Prostate Cancer & Cell Therapy Scientific Advisory Board Member | 1.3yrs | US$941.21k | 0.068% $ 16.1k | |
| Independent Director | 4.8yrs | US$68.21k | 0.0039% $ 912.2 |
4.8yrs
Average Tenure
69yo
Average Age
Experienced Board: ONCT's board of directors are considered experienced (4.8 years average tenure).